Guru Sonpavde1, Gregory R Pond2, Melissa Plets3, Catherine M Tangen3, Maha H A Hussain4, Primo N Lara5, Amir Goldkorn6, Mark G Garzotto7, Philip C Mack5, Celestia S Higano8, Nicholas J Vogelzang9, Ian M Thompson10, Przemyslaw W Twardowski11, Peter J Van Veldhuizen12, Neeraj Agarwal13, Michael A Carducci14, J Paul Monk15, David I Quinn6. 1. University of Alabama at Birmingham, Birmingham, AL. Electronic address: gsonpavde@uabmc.edu. 2. McMaster University, Hamilton, ON, Canada. 3. SWOG Statistical Center, Seattle, WA. 4. University of Michigan, Ann Arbor, MI. 5. UC Davis Cancer Center, Sacramento, CA. 6. University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA. 7. Oregon Health & Science University, Portland, OR. 8. Seattle Cancer Care Alliance/University of Washington, Seattle, WA. 9. Comprehensive Cancer Centers of Nevada, Las Vegas, NV. 10. University of Texas Health Science Center at San Antonio, San Antonio, TX. 11. City of Hope Medical Center, Duarte, CA. 12. University of Kansas, Kansas City, KS. 13. University of Utah, Salt Lake City, UT. 14. Johns Hopkins Kimmel Cancer Center, Baltimore, MD. 15. Ohio State University, Columbus, OH.
Abstract
BACKGROUND: Phase 2 trials evaluating new agents for metastatic castration-resistant prostate cancer (mCRPC) have relied on bone scan and prostate-specific antigen changes to assess activity. Given the increasing detection of measurable disease, Response Evaluation Criteria in Solid Tumors (RECIST) changes warrant consideration to evaluate activity. We validated the association of RECIST 1.0 changes with survival in men with mCRPC receiving docetaxel. PATIENTS AND METHODS: Data for men with measurable disease from the Southwest Oncology Group (SWOG) S0421, a phase 3 trial in men with mCRPC receiving docetaxel and prednisone plus placebo or atrasentan, were used. Cox proportional hazards regression was used to evaluate the association of RECIST 1.0 outcomes within 120 days, ie, unconfirmed partial response (uPR), stable disease, and progressive disease (PD), with overall survival (OS) from day 120, adjusted for prognostic factors. RESULTS: Overall, 326 men were evaluable for landmark analysis, of whom 23 had PD, 230 stable disease, and 73 uPR. OS beyond day 120 was significantly different (P = .004) among these subgroups, with median (95% confidence interval) OS of 7.1 (3.5-8.8), 13.4 (11.4-15.6), and 16.3 (10.0-19.6) months for those with PD, stable disease, and uPR, respectively. In a multivariable model, the hazard ratio (95% confidence interval) for patients with PD was 2.47 (1.42-4.29) compared to patients with an uPR (P = .002). CONCLUSION: The association of RECIST 1.0 changes with OS in men with mCRPC receiving docetaxel was validated. Given limitations of bone scan and prostate-specific antigen alterations, improvements in objective RECIST 1.0 changes should be reported in phase 2 trials before launching phase 3 trials.
BACKGROUND: Phase 2 trials evaluating new agents for metastatic castration-resistant prostate cancer (mCRPC) have relied on bone scan and prostate-specific antigen changes to assess activity. Given the increasing detection of measurable disease, Response Evaluation Criteria in Solid Tumors (RECIST) changes warrant consideration to evaluate activity. We validated the association of RECIST 1.0 changes with survival in men with mCRPC receiving docetaxel. PATIENTS AND METHODS: Data for men with measurable disease from the Southwest Oncology Group (SWOG) S0421, a phase 3 trial in men with mCRPC receiving docetaxel and prednisone plus placebo or atrasentan, were used. Cox proportional hazards regression was used to evaluate the association of RECIST 1.0 outcomes within 120 days, ie, unconfirmed partial response (uPR), stable disease, and progressive disease (PD), with overall survival (OS) from day 120, adjusted for prognostic factors. RESULTS: Overall, 326 men were evaluable for landmark analysis, of whom 23 had PD, 230 stable disease, and 73 uPR. OS beyond day 120 was significantly different (P = .004) among these subgroups, with median (95% confidence interval) OS of 7.1 (3.5-8.8), 13.4 (11.4-15.6), and 16.3 (10.0-19.6) months for those with PD, stable disease, and uPR, respectively. In a multivariable model, the hazard ratio (95% confidence interval) for patients with PD was 2.47 (1.42-4.29) compared to patients with an uPR (P = .002). CONCLUSION: The association of RECIST 1.0 changes with OS in men with mCRPC receiving docetaxel was validated. Given limitations of bone scan and prostate-specific antigen alterations, improvements in objective RECIST 1.0 changes should be reported in phase 2 trials before launching phase 3 trials.
Authors: Charles J Ryan; Shreya Shah; Eleni Efstathiou; Matthew R Smith; Mary-Ellen Taplin; Glenn J Bubley; Christopher J Logothetis; Thian Kheoh; Christine Kilian; Christopher M Haqq; Arturo Molina; Eric J Small Journal: Clin Cancer Res Date: 2011-06-01 Impact factor: 12.531
Authors: P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther Journal: J Natl Cancer Inst Date: 2000-02-02 Impact factor: 13.506
Authors: Susan Halabi; Chen-Yen Lin; W Kevin Kelly; Karim S Fizazi; Judd W Moul; Ellen B Kaplan; Michael J Morris; Eric J Small Journal: J Clin Oncol Date: 2014-01-21 Impact factor: 44.544
Authors: Guru Sonpavde; Gregory R Pond; Andrew J Armstrong; Matthew D Galsky; Lance Leopold; Brian A Wood; Shaw-Ling Wang; Jolanda Paolini; Isan Chen; Edna Chow-Maneval; David J Mooney; Mariajose Lechuga; Matthew R Smith; M Dror Michaelson Journal: BJU Int Date: 2014-07-17 Impact factor: 5.588
Authors: G R Hudes; R Greenberg; R L Krigel; S Fox; R Scher; S Litwin; P Watts; L Speicher; K Tew; R Comis Journal: J Clin Oncol Date: 1992-11 Impact factor: 44.544
Authors: Andrew J Armstrong; Reza Kaboteh; Michael A Carducci; Jan-Erik Damber; Walter M Stadler; Mats Hansen; Lars Edenbrandt; Göran Forsberg; Örjan Nordle; Roberto Pili; Michael J Morris Journal: Urol Oncol Date: 2014-09-16 Impact factor: 3.498
Authors: Pasquale Rescigno; David Lorente; Diletta Bianchini; Roberta Ferraldeschi; Michael P Kolinsky; Spyridon Sideris; Zafeiris Zafeiriou; Semini Sumanasuriya; Alan D Smith; Niven Mehra; Anuradha Jayaram; Raquel Perez-Lopez; Joaquin Mateo; Chris Parker; David P Dearnaley; Nina Tunariu; Alison Reid; Gerhardt Attard; Johann S de Bono Journal: Eur Urol Date: 2016-03-07 Impact factor: 20.096
Authors: Jose Mauricio Mota; Andrew J Armstrong; Steven M Larson; Josef J Fox; Michael J Morris Journal: Prostate Cancer Prostatic Dis Date: 2019-04-29 Impact factor: 5.554